About Sio

Sio Gene Therapies is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating rare neurodegenerative diseases, including GM1 gangliosidosis and Tay-Sachs/Sandhoff disease.

Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.

Our mission is simple:

To combine cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. We are working tirelessly to advance our rare fatal pediatric neurodegenerative programs through clinical development so that patients can access the therapies they need.

Management & Board of Directors

David Nassif, JD

David Nassif, JD

Chief Executive Officer, Chief Financial Officer, General Counsel and member of the Board of Directors
Scroll to Top